Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients
Parkinson’s disease (PD) is the second most common neurodegenerative disease, and mild cognitive impairment (MCI) is a well-established risk factor for the development of dementia in PD. A growing body of evidence suggests that low expression of glucocerebrosidase ( GBA ) promotes the transmission o...
Gespeichert in:
Veröffentlicht in: | Molecular brain 2020-07, Vol.13 (1), p.1-102, Article 102 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Parkinson’s disease (PD) is the second most common neurodegenerative disease, and mild cognitive impairment (MCI) is a well-established risk factor for the development of dementia in PD. A growing body of evidence suggests that low expression of glucocerebrosidase (
GBA
) promotes the transmission of α-synuclein (α-Syn) interpolymers and the progression of PD. However, how
GBA
mutations affect the pathogenesis of PD via abnormal aggregation of α-Syn is unclear, and no clinically valid PD-MCI genetic markers have been identified. Here, we first located a
GBA
eQTL, rs12411216, by analysing DHS, eQTL SNP, and transcription factor binding site data using the UCSC database. Subsequently, we found that rs12411216 was significantly associated with PD-MCI (
P
|
---|---|
ISSN: | 1756-6606 1756-6606 |
DOI: | 10.1186/s13041-020-00637-x |